Dr. Motzer on a Phase II Trial of Nivolumab for mRCC

Dr. Motzer on Nivolumab/Ipilimumab Activity in RCCПодробнее

Dr. Motzer Discusses Nivolumab for mRCCПодробнее

Nivolumab with alternatively scheduled ipilimumab in first-line treatment of advanced RCCПодробнее

Dr. Motzer on Nivolumab Versus Everolimus in Renal Call CarcinomaПодробнее

Nivolumab in Renal Cell CarcinomaПодробнее

PROSPER RCC study of perioperative nivolumab for renal cell carcinoma - future trialПодробнее

Nivolumab in Renal Cell CarcinomaПодробнее

Phase II trial on Nivolumab in mRCC - Dr. Robert Motzer at ASCO 2014Подробнее

Dr. Voss on Phase I/II Trial Data of MEDI0680/Durvalumab Versus Nivolumab in mRCCПодробнее

Ipilimumab/Nivolumab in First-Line mRCCПодробнее

Dr. McDermott on Long-Term Benefit With Nivolumab in RCCПодробнее

Dr Hans Hammers discusses the clinical trial of nivolumab plus ipilimumab in renal cell carcinomaПодробнее

Two Positive Phase III RCC Studies, Nivolumab Approved for NSCLC in Europe, and MoreПодробнее

Dr. Karasic on Phase II Trial of Nivolumab and IpilimumabПодробнее

Immunotherapeutic Combinations for mRCC: IMmotion-151Подробнее

Safety and efficacy of nivolumab in mRCC: Final analysis from the NIVOREN studyПодробнее

Immunotherapy in Renal Cell CarcinomaПодробнее

Frontline Therapy Options for mRCCПодробнее

mRCC Patient Selection for Ipilimumab/NivolumabПодробнее